Heterogeneity in the tumour size dynamics differentiates Vemurafenib, Dabrafenib and Trametinib in metastatic melanoma
H. Mistry, D. Orrell, R. Eftimie
This study uses a mathematical model to analyze tumor size dynamics in metastatic melanoma patients treated with Vemurafenib, Dabrafenib, and Trametinib, revealing differences in tumor shrinkage and resistance development.
bioRxiv · May 17, 2017Cancer Biology